<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880266</url>
  </required_header>
  <id_info>
    <org_study_id>DRM04-HH10</org_study_id>
    <nct_id>NCT03880266</nct_id>
  </id_info>
  <brief_title>A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Journey Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Journey Medical Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of glycopyrronium cloth,&#xD;
      2.4% when used to treat palmar hyperhidrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study assessing the safety and efficacy of glycopyrronium cloth in patients&#xD;
      with palmar hyperhidrosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Actual">May 24, 2019</completion_date>
  <primary_completion_date type="Actual">May 24, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline to Week 2 in Hand Sweating Severity Score</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>The Hand Sweat Severity Score is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis [score on a scale from 0 (better) -10 (worse)].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Hyperhidrosis Disease Severity Scale (HDSS) is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.&#xD;
1 (better), 2, 3, 4 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; average of the change in the gravimetric measurement of sweat produced at baseline compared with Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in Gravimetrically-measured Sweat Production at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; calculation of percentage difference in sweat production at week 2 compared to baseline sweat production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically-measured Sweat Production From Baseline at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; confidence interval represents difference between vehicle and active group</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Palmar Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>Group 1 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium cloth, 2.4%</intervention_name>
    <description>Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium</description>
    <arm_group_label>Group 1 Active</arm_group_label>
    <arm_group_label>Group 2 Active</arm_group_label>
    <arm_group_label>Group 3 Active</arm_group_label>
    <arm_group_label>Group 4 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Pre-saturated 100% polypropylene, nonwoven, fabric cloth</description>
    <arm_group_label>Group 1 Vehicle</arm_group_label>
    <arm_group_label>Group 2 Vehicle</arm_group_label>
    <arm_group_label>Group 3 Vehicle</arm_group_label>
    <arm_group_label>Group 4 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent and assent (for subjects under legal adult age).&#xD;
&#xD;
          2. Age ≥9 years.&#xD;
&#xD;
          3. Primary palmar hyperhidrosis for at least 6 months duration.&#xD;
&#xD;
          4. Average sweat severity score of ≥4 at Baseline.&#xD;
&#xD;
          5. Hyperhidrosis Disease Severity Scale of 3 or 4 at Baseline.&#xD;
&#xD;
          6. Willing to comply with the protocol. Subjects under legal adult age will be assessed&#xD;
             by the investigator as to their ability to comply with the protocol.&#xD;
&#xD;
          7. Male or non-pregnant (negative urine pregnancy test in female subjects of&#xD;
             child-bearing potential), non-lactating females.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have taken or are currently taking glycopyrronium cloth, 2.4%.&#xD;
&#xD;
          2. Prior surgical procedure for hyperhidrosis.&#xD;
&#xD;
          3. Iontophoresis for the palms within 4 weeks of Baseline.&#xD;
&#xD;
          4. Treatment with botulinum toxin (e.g., Botox®) for palmar hyperhidrosis within 1 year&#xD;
             of Baseline.&#xD;
&#xD;
          5. Open wounds or inflammatory lesions on the hands or, any condition that may alter the&#xD;
             barrier function of the skin on the hands.&#xD;
&#xD;
          6. Secondary palmar hyperhidrosis or presence of a condition that may cause secondary&#xD;
             hyperhidrosis (e.g., lymphoma, malaria, severe anxiety not controlled by medication,&#xD;
             carcinoid syndrome, substance abuse, hyperthyroidism).&#xD;
&#xD;
          7. Known history of Sjögren's syndrome or Sicca syndrome.&#xD;
&#xD;
          8. History of glaucoma, inflammatory bowel disease, toxic megacolon, active febrile&#xD;
             illness, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe&#xD;
             ulcerative colitis, toxic megacolon complicating ulcerative colitis or myasthenia&#xD;
             gravis.&#xD;
&#xD;
          9. Men with a history of urinary retention requiring catheterization due to prostatic&#xD;
             hypertrophy or severe obstructive symptoms of prostatic hypertrophy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate Doherty</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Dermatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Dermatology/ ACRC Trials</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <results_first_submitted>October 20, 2020</results_first_submitted>
  <results_first_submitted_qc>February 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2021</results_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03880266/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="P2">
          <title>Group 1 Vehicle</title>
          <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="P3">
          <title>Group 2 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="P4">
          <title>Group 2 Vehicle</title>
          <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="P5">
          <title>Group 3 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
        </group>
        <group group_id="P6">
          <title>Group 3 Vehicle</title>
          <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes</description>
        </group>
        <group group_id="P7">
          <title>Group 4 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
        </group>
        <group group_id="P8">
          <title>Group 4 Vehicle</title>
          <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="13"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="B2">
          <title>Group 1 Vehicle</title>
          <description>Vehicle applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="B3">
          <title>Group 2 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="B4">
          <title>Group 2 Vehicle</title>
          <description>Vehicle applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="B5">
          <title>Group 3 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
        </group>
        <group group_id="B6">
          <title>Group 3 Vehicle</title>
          <description>Vehicle applied to the hands once daily for 14 days: 15 minutes</description>
        </group>
        <group group_id="B7">
          <title>Group 4 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
        </group>
        <group group_id="B8">
          <title>Group 4 Vehicle</title>
          <description>Vehicle applied to the hands once daily for 14 days: 30 minutes</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="13"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="8.95"/>
                    <measurement group_id="B2" value="34.5" spread="15.93"/>
                    <measurement group_id="B3" value="29.2" spread="11.57"/>
                    <measurement group_id="B4" value="47.5" spread="17.56"/>
                    <measurement group_id="B5" value="28.2" spread="12.45"/>
                    <measurement group_id="B6" value="32.5" spread="7.97"/>
                    <measurement group_id="B7" value="26.6" spread="9.54"/>
                    <measurement group_id="B8" value="37.1" spread="13.91"/>
                    <measurement group_id="B9" value="31.1" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hand Sweat Severity Score</title>
          <description>The Hand Sweat Severity Score is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis [score on a scale from 0 (better) -10 (worse)].</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.78" spread="1.646"/>
                    <measurement group_id="B2" value="7.40" spread="0.718"/>
                    <measurement group_id="B3" value="7.56" spread="1.450"/>
                    <measurement group_id="B4" value="8.10" spread="1.920"/>
                    <measurement group_id="B5" value="6.93" spread="1.689"/>
                    <measurement group_id="B6" value="7.37" spread="2.017"/>
                    <measurement group_id="B7" value="7.58" spread="1.399"/>
                    <measurement group_id="B8" value="8.01" spread="1.078"/>
                    <measurement group_id="B9" value="7.37" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Week 2 in Hand Sweating Severity Score</title>
        <description>The Hand Sweat Severity Score is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis [score on a scale from 0 (better) -10 (worse)].</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O5">
            <title>Group 3 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O6">
            <title>Group 3 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O7">
            <title>Group 4 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
          <group group_id="O8">
            <title>Group 4 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 2 in Hand Sweating Severity Score</title>
          <description>The Hand Sweat Severity Score is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis [score on a scale from 0 (better) -10 (worse)].</description>
          <population>Intent to Treat Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="2.199"/>
                    <measurement group_id="O2" value="-0.56" spread="0.730"/>
                    <measurement group_id="O3" value="-1.64" spread="1.410"/>
                    <measurement group_id="O4" value="-3.03" spread="2.161"/>
                    <measurement group_id="O5" value="-2.53" spread="2.223"/>
                    <measurement group_id="O6" value="-2.20" spread="1.084"/>
                    <measurement group_id="O7" value="-1.30" spread="2.062"/>
                    <measurement group_id="O8" value="-1.34" spread="1.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.244</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.76</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.699</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.833</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.94</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2</title>
        <description>Hyperhidrosis Disease Severity Scale (HDSS) is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.&#xD;
1 (better), 2, 3, 4 (worse)</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O5">
            <title>Group 3 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O6">
            <title>Group 3 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O7">
            <title>Group 4 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
          <group group_id="O8">
            <title>Group 4 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Have a ≥2 Grade Improvement in HDSS (Hyperhidrosis Disease Severity Scale) From Baseline at Week 2</title>
          <description>Hyperhidrosis Disease Severity Scale (HDSS) is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.&#xD;
1 (better), 2, 3, 4 (worse)</description>
          <population>Intent to Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.589</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.646</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 2</title>
        <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; average of the change in the gravimetric measurement of sweat produced at baseline compared with Week 2</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O5">
            <title>Group 3 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O6">
            <title>Group 3 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O7">
            <title>Group 4 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
          <group group_id="O8">
            <title>Group 4 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Baseline in Gravimetrically-measured Sweat Production at Week 2</title>
          <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; average of the change in the gravimetric measurement of sweat produced at baseline compared with Week 2</description>
          <population>Intent to Treat Population</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.8" spread="162.54"/>
                    <measurement group_id="O2" value="136.7" spread="320.57"/>
                    <measurement group_id="O3" value="-15.3" spread="53.14"/>
                    <measurement group_id="O4" value="-159.4" spread="354.38"/>
                    <measurement group_id="O5" value="-113.5" spread="164.10"/>
                    <measurement group_id="O6" value="38.1" spread="106.30"/>
                    <measurement group_id="O7" value="-58.6" spread="139.70"/>
                    <measurement group_id="O8" value="102.0" spread="767.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-206.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-451.9</ci_lower_limit>
            <ci_upper_limit>38.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.186</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>144.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.6</ci_lower_limit>
            <ci_upper_limit>366.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-151.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-309.0</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.186</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>160.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-611.2</ci_lower_limit>
            <ci_upper_limit>290.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in Gravimetrically-measured Sweat Production at Week 2</title>
        <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; calculation of percentage difference in sweat production at week 2 compared to baseline sweat production</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O5">
            <title>Group 3 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O6">
            <title>Group 3 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O7">
            <title>Group 4 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
          <group group_id="O8">
            <title>Group 4 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in Gravimetrically-measured Sweat Production at Week 2</title>
          <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; calculation of percentage difference in sweat production at week 2 compared to baseline sweat production</description>
          <population>Intent to Treat Population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" spread="28.26"/>
                    <measurement group_id="O2" value="16.5" spread="60.4"/>
                    <measurement group_id="O3" value="-7.5" spread="65.53"/>
                    <measurement group_id="O4" value="-31.8" spread="51.29"/>
                    <measurement group_id="O5" value="-26.8" spread="39.17"/>
                    <measurement group_id="O6" value="11.4" spread="34.96"/>
                    <measurement group_id="O7" value="-17.7" spread="40.43"/>
                    <measurement group_id="O8" value="21.7" spread="145.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.130</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.42</ci_lower_limit>
            <ci_upper_limit>11.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.518</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>24.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.62</ci_lower_limit>
            <ci_upper_limit>103.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.061</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-38.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.32</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.366</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-39.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-128.40</ci_lower_limit>
            <ci_upper_limit>49.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically-measured Sweat Production From Baseline at Week 2</title>
        <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; confidence interval represents difference between vehicle and active group</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
          </group>
          <group group_id="O5">
            <title>Group 3 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O6">
            <title>Group 3 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes</description>
          </group>
          <group group_id="O7">
            <title>Group 4 Active</title>
            <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
          <group group_id="O8">
            <title>Group 4 Vehicle</title>
            <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Have at Least a 50% Reduction in Gravimetrically-measured Sweat Production From Baseline at Week 2</title>
          <description>Gravimetrically measured sweat production is based on the mean of the right and left hand measurements; confidence interval represents difference between vehicle and active group</description>
          <population>Intent to Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.515</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.560</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.245</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.290</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through Week 2</time_frame>
      <desc>All subjects who are randomized and receive at least one confirmed dose of study drug will be included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="E2">
          <title>Group 1 Vehicle</title>
          <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="E3">
          <title>Group 2 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="E4">
          <title>Group 2 Vehicle</title>
          <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)</description>
        </group>
        <group group_id="E5">
          <title>Group 3 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes</description>
        </group>
        <group group_id="E6">
          <title>Group 3 Vehicle</title>
          <description>Vehicle cloth applied to the hands once daily for 14 days: 15 minutes</description>
        </group>
        <group group_id="E7">
          <title>Group 4 Active</title>
          <description>Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes</description>
        </group>
        <group group_id="E8">
          <title>Group 4 Vehicle</title>
          <description>Vehicle cloth applied to the hands once daily for 14 days: 30 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compensatory sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jordan Adajar</name_or_title>
      <organization>Dermira, Inc</organization>
      <phone>650-421-2919</phone>
      <email>jordan.adajar@dermira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

